Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Director departure
Merger agrmnt [a]
Appointed director
Foamix Pharmaceuticals Ltd. (FOMX) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/23/2020 EFFECT Form EFFECT - Notice of Effectiveness:
03/19/2020 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
03/18/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/18/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/18/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/18/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/18/2020 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/12/2020 10-K Annual Report for the period ended December 31, 2019
03/12/2020 8-K Quarterly results
03/09/2020 8-K Quarterly results
03/09/2020 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
03/03/2020 425 Form 425 - Prospectuses and communications, business combinations:
02/28/2020 425 Form 425 - Prospectuses and communications, business combinations:
02/18/2020 GN Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea
02/14/2020 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2020 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/14/2020 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/06/2020 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
Docs: "Foamix and Menlo Announce Shareholder Approval of Proposed Merger"
02/06/2020 425 Form 425 - Prospectuses and communications, business combinations:
02/06/2020 425 Form 425 - Prospectuses and communications, business combinations:
01/31/2020 425 Form 425 - Prospectuses and communications, business combinations:
01/28/2020 425 Form 425 - Prospectuses and communications, business combinations:
01/28/2020 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
01/17/2020 425 Form 425 - Prospectuses and communications, business combinations:
01/17/2020 GN Foamix Announces OrbiMed's Support of Merger with Menlo Therapeutics
01/16/2020 425 Form 425 - Prospectuses and communications, business combinations:
01/16/2020 425 Form 425 - Prospectuses and communications, business combinations:
01/15/2020 425 Form 425 - Prospectuses and communications, business combinations:
01/14/2020 SC 13G/A Delaware Street Capital Master Fund, L.P. reports a 5.5% stake in Foamix Pharmaceuticals Ltd.
01/14/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Foamix Announces AMZEEQ TM Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S."
01/14/2020 GN Foamix Announces AMZEEQ™ (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.
01/10/2020 425 Form 425 - Prospectuses and communications, business combinations:
01/10/2020 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
01/09/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Foamix Announces AMZEEQ TM Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy